Trial Profile
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naive HIV-1-infected Participants
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 30 Apr 2019 Results of post hoc analysis using VL data obtained from the timepoints shared by A5353, SPRING 1 and SINGLE trial published in the Journal of Antimicrobial Chemotherapy
- 18 Jan 2019 Results assessing efficacy and safety of dolutegravir plus lamivudine at week 48, published in the Journal of Antimicrobial Chemotherapy.
- 31 Oct 2018 Results comparing viral decay with dolutegravir plus lamivudine versus dolutegravir-based triple therapy using data from A5353, SPRING-1 and SINGLE (n=588) presented at the 14th International Congress on Drug Therapy and HIV Infection